Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,500 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $13.69, for a total value of $20,535.00. Following the completion of the sale, the executive vice president now directly owns 123,567 shares of the company’s stock, valued at $1,691,632.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Fady Ibraham Malik also recently made the following trade(s):

  • On Thursday, August 8th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $13.52, for a total value of $20,280.00.
  • On Thursday, July 11th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $11.26, for a total value of $16,890.00.

Shares of NASDAQ CYTK traded down $0.16 during mid-day trading on Friday, hitting $14.09. 493,400 shares of the company were exchanged, compared to its average volume of 368,416. The company has a quick ratio of 8.42, a current ratio of 8.42 and a debt-to-equity ratio of 12.35. The stock has a 50 day simple moving average of $12.98 and a 200-day simple moving average of $10.19. Cytokinetics, Inc. has a 1-year low of $5.75 and a 1-year high of $14.94. The firm has a market cap of $836.17 million, a price-to-earnings ratio of -7.23 and a beta of 1.64.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Cytokinetics had a negative return on equity of 575.21% and a negative net margin of 308.73%. The company had revenue of $7.14 million for the quarter, compared to analyst estimates of $6.81 million. Analysts anticipate that Cytokinetics, Inc. will post -2 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Everence Capital Management Inc. acquired a new stake in shares of Cytokinetics during the first quarter worth $133,000. SG Americas Securities LLC acquired a new stake in shares of Cytokinetics during the first quarter worth $151,000. Comerica Bank lifted its holdings in shares of Cytokinetics by 3.5% during the first quarter. Comerica Bank now owns 54,154 shares of the biopharmaceutical company’s stock worth $472,000 after purchasing an additional 1,808 shares during the period. South Dakota Investment Council lifted its holdings in shares of Cytokinetics by 5.7% during the first quarter. South Dakota Investment Council now owns 472,958 shares of the biopharmaceutical company’s stock worth $3,826,000 after purchasing an additional 25,300 shares during the period. Finally, Wasatch Advisors Inc. lifted its holdings in shares of Cytokinetics by 29.8% during the first quarter. Wasatch Advisors Inc. now owns 3,188,487 shares of the biopharmaceutical company’s stock worth $25,795,000 after purchasing an additional 731,682 shares during the period. 66.26% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on CYTK. BidaskClub downgraded Cytokinetics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 16th. Morgan Stanley set a $16.00 price objective on Cytokinetics and gave the company a “hold” rating in a report on Friday, August 9th. Zacks Investment Research raised Cytokinetics from a “sell” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC set a $16.00 price objective on Cytokinetics and gave the company a “buy” rating in a report on Friday, August 9th. Finally, ValuEngine raised Cytokinetics from a “buy” rating to a “strong-buy” rating in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Cytokinetics currently has an average rating of “Buy” and a consensus price target of $17.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Featured Story: What is the Fibonacci sequence?

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.